# reload+after+2024-01-21 09:46:03.826556
address1§4275 Executive Square
address2§Suite 300
city§La Jolla
state§CA
zip§92037
country§United States
phone§858 373 1500
fax§858 404 0048
website§https://www.medicinova.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
fullTimeEmployees§13
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Yuichi  Iwaki M.D., Ph.D.', 'age': 73, 'title': 'Co-Founder, President, CEO & Executive Director', 'yearBorn': 1950, 'fiscalYear': 2022, 'totalPay': 933046, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kazuko  Matsuda M.D., M.P.H., Ph.D.', 'age': 57, 'title': 'Chief Medical Officer & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 653654, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason J. Kruger CPA', 'age': 46, 'title': 'CFO & Principal Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David H. Crean M.B.A., Ph.D.', 'age': 58, 'title': 'Chief Business Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Mr. John  O'Neil CPA", 'title': 'Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§10
compensationRisk§7
shareHolderRightsRisk§5
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.783
priceToSalesTrailing12Months§75.53114
currency§USD
dateShortInterest§1702598400
forwardEps§-45.24
pegRatio§-0.37
exchange§NGM
quoteType§EQUITY
shortName§MediciNova, Inc.
longName§MediciNova, Inc.
firstTradeDateEpochUtc§1165588200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c2932104-58fe-3a03-8298-c9f1617dc654
gmtOffSetMilliseconds§-18000000
targetHighPrice§27.0
targetLowPrice§6.0
targetMeanPrice§16.5
targetMedianPrice§16.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§18.741
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
